WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Michael Pollock vice president of real world outcomes. Pollock is responsible for directing and enhancing PPD’s capabilities in health outcomes and evidence-based medicine to help biopharmaceutical clients optimize market and patient access to novel therapies.
“PPD is continually strengthening its offerings across the real world outcomes spectrum, and Michael brings a unique background to this role, having held senior positions both in sales and marketing, and in health economics for both large pharmaceutical and biotechnology companies,” said Rob Dow, M.D., PPD’s senior vice president of medical affairs. “He has the knowledge, experience and leadership skills to help grow PPD’s real world outcomes solutions, as we drive value and fuel success for clients.”
PPD tailors real world outcomes studies for each client, delivering innovative, flexible designs that meet specific objectives, marketplace needs and regulatory requirements in the complex post-approval environment. Global late stage services include: data management; expanded access programs; post-approval studies; investigator-initiated studies; pharmacoeconomics and health outcomes studies; registries and observational studies; research to support risk evaluation and mitigation strategies; post-authorization safety studies; patient adherence; large simple trials; long-term safety; and comparative effectiveness research.
Most recently, Pollock was president of Reynolds Pollock & Associates, a health outcomes research and market access strategy consulting company. Previous biopharmaceutical industry roles include: vice president of global health economics at Biogen Idec; vice president of sales and marketing at Elan Pharmaceuticals; vice president of sales and marketing and information services at Oncology Therapeutics Network, a division of Bristol-Myers Squibb; and director and head of worldwide health economics at Glaxo Wellcome (now GlaxoSmithKline).
Pollock earned a bachelor’s degree in applied biology from the University of Ulster in Northern Ireland and completed graduate work in marketing at the College of Marketing and Design in Dublin, Ireland. An adjunct professor at the Rady School of Management at the University of California, San Diego, he teaches courses on health economics and the biotechnology industry.
About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s real world outcomes services, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
